Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.76 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.76 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.76 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | MLNR | O43193 | 1/20 | 0.62 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.62 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.62 |
| ▸ | ESR1 | P03372 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.62 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.62 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.62 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | HTR1A | P08908 | 1/20 | 0.62 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11133286 | 1.00 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL11133547 | 1.00 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL8253409 | 1.00 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL9843400 | 1.00 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL10995616 | 1.00 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL8242450 | 0.90 | SLC6A2 (0.66) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL18888711 | 0.89 | SLC6A2 (0.64) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL3365835 | 0.87 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL7932101 | 0.87 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7932104 | 0.87 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0813543-A1 | BIS-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-12-29 | — | — | EP | claimed |
| EP-0386997-B1 | Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation, and as immunosuppressants | PFIZER (US) | 1997-03-19 | — | — | EP | claimed |
| WO-1996028464-A1 | BIS-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-09-19 | — | — | WO | claimed |
| EP-0030081-B1 | ANTIDEPRESSANT DERIVATIVES OF CIS-4-PHENYL-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. (US) | 1983-03-02 | — | — | EP | claimed |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2013-10-31 | — | — | US | disclosed |
| US-8475804-B2 | Compositions and methods for treatment of filovirus-mediated diseases | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2013-07-02 | — | — | US | disclosed |
| US-8475804-B2 | Compositions and methods for treatment of filovirus-mediated diseases | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2013-07-02 | — | — | US | disclosed |
| WO-2011131693-A2 | COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO SPECIFIC NEURON TYPES | NLIFE THERAPEUTICS, S.L. (ES) | 2011-10-27 | — | — | WO | disclosed |
| EP-2380595-A1 | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types | Nlife Therapeutics S.L. (ES) | 2011-10-26 | — | — | EP | disclosed |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | ZALICUS INC. | 2011-02-03 | — | — | US | disclosed |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | ZALICUS INC. | 2011-02-03 | — | — | US | disclosed |
| US-7786119-B2 | Drug conjugates of ion channel modulating compounds | CARDIOME PHARMA CORP. (CA) | 2010-08-31 | — | — | US | disclosed |
| US-20080287406-A1 | Compositions and methods for treating medical conditions | ZALICUS INC. | 2008-11-20 | — | — | US | disclosed |
| US-20080287406-A1 | Compositions and methods for treating medical conditions | ZALICUS INC. | 2008-11-20 | — | — | US | disclosed |
| WO-2008133884-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008118423-A1 | COMPOSITIONS AND METHODS FOR TREATING MEDICAL CONDITIONS | COMBINATORX, INCORPORATED (US) | 2008-10-02 | — | — | WO | disclosed |
| EP-0386997-B1 | Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation, and as immunosuppressants | PFIZER (US) | 1997-03-19 | — | — | EP | disclosed |
| US-4981870-A | Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants | PFIZER INC. (US) | 1991-01-01 | — | — | US | disclosed |
| EP-0030081-B1 | ANTIDEPRESSANT DERIVATIVES OF CIS-4-PHENYL-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. (US) | 1983-03-02 | — | — | EP | disclosed |
| EP-0030081-A1 | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine and pharmaceutical compositions thereof | PFIZER INC. (US) | 1981-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | SLC6A2 3501/4885SLC6A4 4537/4885SLC6A3 4289/4885 |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | SLC6A2 3501/4885SLC6A4 4537/4885SLC6A3 4289/4885 |
| US-20080287406-A1 | Compositions and methods for treating medical conditions | S100B, S100P, S100A6 | SLC6A2 1042/4885SLC6A4 761/4885SLC6A3 3786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.